CJ to heighten effort to boost pharmaceutical and biosimilar sectors

Published: 2012-01-17 06:57:00

Updated: 2012-01-17 06:57:00

CJ Cheiljedang Corp., Korea's leading food manufacturer, has recently unveiled a set of plans to nurture its pharmaceutical and biosimilar sectors as one of CJ’s core businesses.

“We will boost the sales of pharmaceutical and biosimlar products by spending more money in our research and develo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK